# US 11,896,609 B2 · Pharmaceutical composition for treating inflammatory diseases comprising germanium telluride nanosheets coated with polyvinylpyrrolidone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,609 B2
- Document ID: US11896609B2
- Status: Granted
- Kind: B2
- Application number: 17/893,937
- Filed: 2022-08-23
- Published: 2023-03-16
- Granted: 2024-02-13
- Earliest claimed: 2021-08-24
- Assignees: Industry-Academic Cooperation Foundation
- Applicants: Industry-Academic Cooperation Foundation
- Inventors: Kyung-Hwa Yoo; Jun Ho Song; Yong-Beom Park; Sun-Mi Lee; Chin Hee Mun; Taejun Yoon
- Web page: https://patentgrep.com/patent/US11896609B2

## CPC

- A61K 33/24: Heavy metals; Compounds thereof
- A61K 9/0029: {Parenteral nutrition; Parenteral nutrition compositions as drug carriers}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 9/5115: {Inorganic compounds}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a composition for treating inflammatory diseases comprising germanium telluride nanosheets coated with polyvinylpyrrolidone, and the nanosheets have excellent anti-inflammatory and thus are excellent in treating inflammatory bowel disease and psoriasis.

## Claims

### Claim 1

A method of treating inflammatory diseases, comprising administering a pharmaceutically effective amount of a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprise a single layer of germanium telluride nanosheets coated with polyvinylpyrrolidone as an active ingredient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inflammatory diseases are is one or more diseases selected from the group consisting of inflammatory bowel disease, psoriasis, atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inflammatory bowel diseases are Crohn's disease or ulcerative colitis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nanosheets suppress the expression of pro-inflammatory factors and increases the expression of anti-inflammatory factors.

### Claim 5 (depends on 4)

The method of claim 4, wherein the pro-inflammatory factors are is selected from the group consisting inducible nitric oxide synthase (iNOS), tumor necrosis factor-α(TNF-α) and interleukin-1β.

### Claim 6 (depends on 4)

The method of claim 4, wherein the anti-inflammatory factors are Arginasel (Arg 1) or cluster of differentiation 206 (CD206).

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is a formulation for oral or parenteral administration.